CN1527711A - 用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物 - Google Patents

用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物 Download PDF

Info

Publication number
CN1527711A
CN1527711A CNA028110196A CN02811019A CN1527711A CN 1527711 A CN1527711 A CN 1527711A CN A028110196 A CNA028110196 A CN A028110196A CN 02811019 A CN02811019 A CN 02811019A CN 1527711 A CN1527711 A CN 1527711A
Authority
CN
China
Prior art keywords
pharmacologically acceptable
derivatives
range
active ingredient
galantamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028110196A
Other languages
English (en)
Chinese (zh)
Inventor
Լ��ϣķ��Ī����
约阿希姆·莫尔曼
¿
赫尔曼·穆克
��ŷƤ��
克劳斯·欧皮兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HF Arzneimittelforschung GmbH and Co KG
Original Assignee
HF Arzneimittelforschung GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HF Arzneimittelforschung GmbH and Co KG filed Critical HF Arzneimittelforschung GmbH and Co KG
Publication of CN1527711A publication Critical patent/CN1527711A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
CNA028110196A 2001-06-18 2002-06-15 用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物 Pending CN1527711A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129265A DE10129265A1 (de) 2001-06-18 2001-06-18 Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
DE10129265.1 2001-06-18

Publications (1)

Publication Number Publication Date
CN1527711A true CN1527711A (zh) 2004-09-08

Family

ID=7688529

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028110196A Pending CN1527711A (zh) 2001-06-18 2002-06-15 用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物

Country Status (27)

Country Link
US (1) US20040192683A1 (https=)
EP (1) EP1397138B1 (https=)
JP (1) JP2005500298A (https=)
KR (1) KR20040010744A (https=)
CN (1) CN1527711A (https=)
AR (1) AR034493A1 (https=)
AT (1) ATE286397T1 (https=)
AU (1) AU2002323873B2 (https=)
BR (1) BR0211008A (https=)
CA (1) CA2450787C (https=)
CZ (1) CZ299951B6 (https=)
DE (2) DE10129265A1 (https=)
EA (1) EA006647B1 (https=)
ES (1) ES2236551T3 (https=)
HU (1) HUP0400865A3 (https=)
IL (2) IL159345A0 (https=)
MX (1) MXPA03011825A (https=)
MY (1) MY129726A (https=)
NO (1) NO20035458D0 (https=)
NZ (1) NZ529944A (https=)
PL (1) PL367207A1 (https=)
PT (1) PT1397138E (https=)
SK (1) SK287180B6 (https=)
TW (1) TWI325320B (https=)
UA (1) UA76753C2 (https=)
WO (1) WO2002102388A2 (https=)
ZA (1) ZA200309232B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194930A (zh) * 2019-04-12 2021-07-30 索非药剂有限公司 用于治疗依赖的含有植物生物碱的口服药物组合物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
DE10318714B4 (de) * 2003-04-25 2006-03-23 Hf Arzneimittelforschung Gmbh Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches
DE10354894A1 (de) * 2003-11-24 2005-07-07 Hf Arzneimittelforschung Gmbh Orale Formulierungen des Desoxypeganins und deren Anwendungen
DE102004048927A1 (de) * 2004-10-06 2006-04-20 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Kombination enthaltend Desoxypeganin und Cyp2D6 Inhibitoren
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
CN102408548B (zh) 2005-09-01 2013-05-15 布勒公司 聚对苯二甲酸乙二醇酯的制造方法
EP1937226A2 (en) * 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
CA2781830C (en) 2009-02-12 2018-03-27 Indiana University Research & Technology Corporation Materials and methods for treating developmental disorders including comorbid and idiopathic autism
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
MX346203B (es) * 2010-09-28 2017-03-09 Depomed Inc Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior.
SMT202500474T1 (it) * 2010-12-03 2026-01-12 Nalpropion Pharmaceuticals Llc Aumento della biodisponibilità farmacologica nella terapia con naltrexone
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
TWI678202B (zh) * 2016-12-14 2019-12-01 陸汝斌 組合物用於製備治療酒癮或酒精濫用之藥物的用途
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
DE3843239C1 (https=) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
EP0424179A3 (en) * 1989-10-20 1991-12-27 John William Olney Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration
US5519017A (en) * 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1996012692A1 (de) * 1994-10-21 1996-05-02 Waldheim Pharmazeutika Gesellschaft M.B.H. VERFAHREN ZUM HERSTELLEN VON DERIVATEN DES 4a,5,9,10,11,12,-HEXAHYDRO-6H-BENZOFURO[3a,3,2-ef][2]BENZAZEPINS
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP0945133A1 (en) * 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
WO1999054280A1 (en) * 1998-04-17 1999-10-28 Kenneth Curry Cubane derivatives as metabotropic glutamate receptor antagonists and process for their preparation
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
DE19906979B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Verwendung von Desoxypeganin zur Behandlung der Nikotinabhängigkeit
DE19906978B4 (de) * 1999-02-19 2004-07-08 Lts Lohmann Therapie-Systeme Ag Pharmazeutische Zusammensetzung enthaltend Desoxypeganin zur Behandlung der Drogenabhängigkeit

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194930A (zh) * 2019-04-12 2021-07-30 索非药剂有限公司 用于治疗依赖的含有植物生物碱的口服药物组合物

Also Published As

Publication number Publication date
PL367207A1 (en) 2005-02-21
CA2450787A1 (en) 2002-12-27
SK15652003A3 (sk) 2004-04-06
ATE286397T1 (de) 2005-01-15
SK287180B6 (sk) 2010-02-08
IL159345A (en) 2009-02-11
CA2450787C (en) 2009-06-02
IL159345A0 (en) 2004-06-01
DE10129265A1 (de) 2003-01-02
TWI325320B (en) 2010-06-01
MXPA03011825A (es) 2005-03-07
EP1397138B1 (de) 2005-01-05
HK1063292A1 (en) 2004-12-24
HUP0400865A2 (hu) 2004-07-28
WO2002102388A2 (de) 2002-12-27
CZ20033390A3 (en) 2004-03-17
KR20040010744A (ko) 2004-01-31
EP1397138A2 (de) 2004-03-17
ES2236551T3 (es) 2005-07-16
ZA200309232B (en) 2004-07-21
US20040192683A1 (en) 2004-09-30
DE50201958D1 (de) 2005-02-10
JP2005500298A (ja) 2005-01-06
AR034493A1 (es) 2004-02-25
EA006647B1 (ru) 2006-02-24
HUP0400865A3 (en) 2011-03-28
BR0211008A (pt) 2004-10-26
WO2002102388A3 (de) 2003-09-18
NZ529944A (en) 2007-02-23
EA200400041A1 (ru) 2004-04-29
AU2002323873B2 (en) 2006-11-16
PT1397138E (pt) 2005-04-29
CZ299951B6 (cs) 2009-01-07
UA76753C2 (uk) 2006-09-15
NO20035458D0 (no) 2003-12-08
MY129726A (en) 2007-04-30

Similar Documents

Publication Publication Date Title
CN1527711A (zh) 用于药物治疗成瘾性物质或麻醉剂成瘾的活性成分组合物
EP0897726B1 (en) Antipruritic agent
RU2095062C1 (ru) Блокатор синдрома отмены, являющегося результатом привыкания к чрезмерному потреблению лекарств или веществ, вызывающих привыкание, фармакологическая композиция на его основе и способ облегчения или предотвращения синдрома отмены
JP2000508341A (ja) 片頭痛の治療法及び薬効の強化組成物
EA003142B1 (ru) Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
JP2006131545A (ja) 神経因性疼痛治療剤
EP2130539A1 (en) Therapeutic tablet for postherpetic neuralgia and method of treating postherpetic neuralgia
CN1527712A (zh) 用于药物治疗尼古丁依赖的活性成分组合物
JP4362457B2 (ja) 神経因性疼痛治療剤
CN1771029A (zh) 用于治疗酒精滥用的活性物质组合物及疗法
JP2002255820A (ja) モノアミン作動性神経の活性化剤
HK1063292B (en) Active ingredient combination (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcotics
HK1209058B (en) Compositions for treating drug addiction and improving addiction-related behavior
HK1176285A1 (en) Compositions for treating drug addiction and improving addiction-related behavior

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20040908